SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

被引：0
|
作者：
Kruse, CG [1 ]
Tuinstra, T [1 ]
Herremans, A [1 ]
van Vliet, B [1 ]
Long, SK [1 ]
van der Heijden, JA [1 ]
Hesselink, MB [1 ]
机构：
[1] Solvay Pharmaceut, Res Labs, Weesp, Netherlands
来源：
SCHIZOPHRENIA RESEARCH | 2003年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0920-9964(03)80853-8
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [1] SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition:: in vitro and in vivo neurochemistry
    Hesselink, MB
    Van Vliet, B
    Kruse, CG
    Long, SK
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S319 - S319
  • [2] SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition
    van Hes, R
    Smid, P
    Stroomer, CNJ
    Tipker, K
    Tulp, MTM
    van der Heyden, JAM
    McCreary, AC
    Hesselink, MB
    Kruse, CG
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (03) : 405 - 408
  • [3] SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity
    Tuinstra, T
    Herremans, AHJ
    Van der Heyden, JAM
    McCreary, AC
    Hesselink, MB
    Kruse, CG
    Long, SK
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S296 - S296
  • [4] Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
    Yan, Yinfa
    Zhou, Ping
    Rotella, David P.
    Feenstra, Rolf
    Kruse, Chris G.
    Reinders, Jan-Hendrik
    van der Neut, Martina
    Lai, Margaret
    Zhang, Jean
    Kowal, Dianne M.
    Carrick, Tikva
    Marquis, Karen L.
    Pausch, Mark H.
    Robichaud, Albert J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2983 - 2986
  • [5] Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyllpiperazines, novel potential Antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition
    Smid, P
    Coolen, HKAC
    Keizer, HG
    van Hes, R
    de Moes, JP
    den Hartog, AP
    Stork, B
    Plekkenpol, RH
    Niemann, LC
    Stroomer, CNJ
    Tulp, MTM
    van Stuivenberg, HH
    McCreary, AC
    Hesselink, MB
    Herremans, AHJ
    Kruse, CG
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) : 6855 - 6869
  • [6] Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition
    Rami Hamati
    Mostafa El Mansari
    Pierre Blier
    Neuropsychopharmacology, 2020, 45 : 2098 - 2105
  • [7] Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition
    Hamati, Rami
    El Mansari, Mostafa
    Blier, Pierre
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (12) : 2098 - 2105
  • [8] MEDI 263-Synthesis, SAR and biological properties of 1-heteroaryl-4-[u-(1H-indol-3-yl)-alkyl]-piperazines, novel potential antipsychotics combining potent Dopamine D2 receptor antagonism with potent Serotonin reuptake inhibition
    Smid, Pieter
    Coolen, Hein K. A. C.
    van Hes, Rolf
    Kruse, Chris G.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [9] SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist:: In vitro and in vivo neuropharmacology
    Glennon, J
    McCreary, AC
    Ronken, E
    Siarey, R
    Hesselink, MB
    Feenstra, R
    Van Vliet, B
    Long, SK
    Kruse, CG
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S277 - S277
  • [10] Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
    Prabhu, Varun V.
    Madhukar, Neel S.
    Gilvary, Coryandar
    Kline, C. Leah B.
    Oster, Sophie
    El-Deiry, Wafik S.
    Elemento, Olivier
    Doherty, Faye
    VanEngelenburg, Alexander
    Durrant, Jessica
    Tarapore, Rohinton S.
    Deacon, Sean
    Charter, Neil
    Jung, Jinkyu
    Park, Deric M.
    Gilbert, Mark R.
    Rusert, Jessica
    Wechsler-Reya, Robert
    Arrillaga-Romany, Isabel
    Batchelor, Tracy T.
    Wen, Patrick Y.
    Oster, Wolfgang
    Allen, Joshua E.
    CLINICAL CANCER RESEARCH, 2019, 25 (07) : 2305 - 2313
12345